Effect of Tegafur–Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study
Annals of Thoracic and Cardiovascular Surgery · 2024
DOI: 10.5761/atcs.oa.23-00134 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Annals of Thoracic and Cardiovascular Surgery, 2024. Verfasst von Masaya Aoki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Thoracic Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Kagoshima, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma, Adenocarcinoma of Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE: Tegafur-uracil (UFT) is the standard postoperative adjuvant therapy for stage IB lung adenocarcinoma (LUAD) in Japan. This study aimed to determine whether UFT is effective in stage IB LUAD with and without epidermal growth factor receptor (EGFR) mutations. METHODS: This retrospective study included 169 patients with stage IB LUAD who underwent complete resection at our department between 2010 and 2021. We investigated the clinicopathological and prognostic impact of EGFR mutations as well as the postoperative use of UFT. RESULTS: EGFR mutation-positive cases tended to show a higher cumulative recurrence rate than EGFR mutation-negative cases (p = 0.081), while overall survival was comparable between the groups (p = 0.238). In the entire cohort, UFT administration was not an independent prognostic factor in the multivariate regression analysis (p = 0.112). According to a stratification analysis, UFT administration was independently associated with favorable overall survival (p = 0.031) in EGFR mutation-negative cases, while it was not associated with recurrence-free survival (p = 0.991) or overall survival (p = 0.398) in EGFR mutation-positive cases. CONCLUSION: UFT administration can improve the prognosis of EGFR mutation-negative LUAD but not EGFR mutation-positive LUAD. Thus, clinical trials of adjuvant-targeted therapy for EGFR mutation-positive stage IB LUAD should also be conducted in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Thoracic Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Kagoshima, Japan.
- Department of Pulmonary Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Kagoshima, Japan.
Zitieren
APA
Aoki, M., Miyata, R., Kamimura, G., Harada Takeda, A., Suetsugu, T., Mizuno, K., & Ueda, K. (2024). Effect of Tegafur–Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study. Annals of Thoracic and Cardiovascular Surgery. https://doi.org/10.5761/atcs.oa.23-00134
Vancouver
Aoki M, Miyata R, Kamimura G, Harada Takeda A, Suetsugu T, Mizuno K, et al. Effect of Tegafur–Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study. Annals of Thoracic and Cardiovascular Surgery. 2024. doi:10.5761/atcs.oa.23-00134
BibTeX
@article{Aoki2024,
author = {Aoki, Masaya and Miyata, Ryo and Kamimura, Go and Harada Takeda, Aya and Suetsugu, Takayuki and Mizuno, Keiko and Ueda, Kazuhiro},
title = {Effect of Tegafur–Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study},
journal = {Annals of Thoracic and Cardiovascular Surgery},
year = {2024},
doi = {10.5761/atcs.oa.23-00134}
}
EUVIMED